Pancreatic Cancer

Clinical Trial Shows Irofulven Holds Promise

Published in Cancer Weekly, November 28th, 2000

Results from a Phase II clinical trial of irofulven, an anti-cancer agent developed by MGI Pharma, Inc. (MOGN), demonstrated anti-tumor activity in patients with advanced pancreatic cancer who were refractory to gemcitabine (Gemzar), the current first-line chemotherapy approved for treatment of pancreatic cancer.

Released at the 11th U.S. National Cancer Institute (NCI)-EORTC-AACR Symposium on New Drugs in Cancer Therapy in Amsterdam, The Netherlands, the results showed that 10 of the 53 patients enrolled in the study achieved six-month survival, the primary endpoint for the trial. Equally important, two patients demonstrated objective responses: one patient...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-11-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry